anti-CD30 ADC

Anti-CD30 antibody-drug conjugates (ADCs) are a class of targeted cancer therapies designed to deliver cytotoxic agents specifically to cells expressing the CD30 antigen (TNFRSF8). CD30 is a member of the tumor necrosis factor receptor superfamily and is a validated clinical target, particularly in Hodgkin lymphoma and systemic anaplastic large cell lymphoma. These conjugates typically consist of a CD30-specific monoclonal antibody covalently linked to a potent cytotoxin, such as the microtubule inhibitor monomethyl auristatin E (MMAE) or F (MMAF). Upon binding to the target cell, the ADC is internalized via endocytosis, and the payload is released (often following cleavage of the linker by lysosomal proteases), inducing cell cycle arrest and apoptosis. Research in this area, notably by companies like Seattle Genetics, continues to investigate novel auristatin derivatives and linkers to improve activity in efflux-positive (MDR+) models and leverage bystander killing effects.

Other names

anti-CD30 ADCanti-CD-30 ADCanti-CD 30 ADCCD30-targeted antibody-drug conjugateCD-30-targeted antibody-drug conjugateCD 30-targeted antibody-drug conjugate